Advancing Type 2 Diabetes Care With Modern Insulins

Goals

Type 2 Diabetes Is Progressive

Most Patients Are Not Achieving HbA1C < 7%

DCCT Results: HbA1c and Relative Risk of Diabetic Complicationsa,b

By the Time of Diagnosis, β-Cell Decline Exceeds 50%

Most Patients With T2D Will Eventually Need Insulin

Basal Insulin Therapy in T2D

Basal Insulin Improves Glycemic Control

Basal Insulin Replacement Therapy

Currently Available Basal Insulins

Time-action Profiles Illustrate Variability

Limitations of Current Basal Insulins

How Often Does Hypoglycemia Occur?

When Does Hypoglycemia Occur?

Hypoglycemia Is Associated With ECG Abnormalities

Cost of Hypoglycemia

Insulin Analogs Are Associated With Lower Rates of

Hypoglycemia

In Search of Improved Pharmacokinetic/Pharmacodyna

mic Profiles

Why We Need Better Basal Insulins

Novel Basal Insulins on the Horizon

Desired Properties for A Basal Insulin Product Relative to Existing

Therapy

Similar Outcomes With Flexible and Fixed Once-Daily Degludec*

Dosing

Pegylated Lispro* vs Glargine in Adults With T2D at 12 Weeks

Investigational New Insulin Glargine U300 (300 U/mL, Gla-

300)

Glargine U300

Benefits of Newer Basal Insulins

Take-home Messages

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)